longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

TRANSCENTA-B

06628

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -2.07, within the reasonable range, cheaper than 43.24% of the time in the past 3 years, and the industry ranks 28/78, the industry Median -5.53.

-2.07xP/E
HK$0.85Stock price
HK$-0.41Earnings per share
-2.07xP/E
Stock priceHK$0.85Earnings per shareHK$-0.41

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-2.27x
Typical range
-3.71x–-1.26x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0163326489652

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
09926HKAKESO
-77.43x83.25%HK$86.22B
09688HKZAI LAB
-14.47x505.86%HK$21.36B
07666HKMETIS TECHBIO-P
-50.56x97.57%HK$20.58B
01877HKJUNSHI BIO
-38.02x84.85%HK$17.60B
09606HKDUALITYBIO-B
-9.34x83.50%HK$15.47B
09887HKLEADS BIOLABS-B
-40.12x9.00%HK$12.33B
06855HKASCENTAGE
-7.21x18.21%HK$12.19B
02627HKAB&B BIO-TECH-B
-46.87x--HK$11.54B
01672HKASCLETIS-B
-15.52x78.59%HK$10.57B
01952HKEVEREST MED
-162.89x324.61%HK$10.11B
02595HKGENFLEET-B
-6.57x78.96%HK$9.96B
02616HKCSTONE PHARMA-B
-20.11x1.96%HK$9.71B
06938HKRIBOLIFE-B
-49.12x29.88%HK$9.59B
02493HKMABWELL-B
-8.50x--HK$9.19B
01779HKLONGBIO-B
-32.50x--HK$8.09B
09966HKALPHAMAB-B
-39.78x--HK$8.06B
02335HKMICOT PHARMA-B
-19.05x37.50%HK$7.99B
02171HKCARSGEN-B
-72.17x51.12%HK$7.41B
06872HKTENNOR THERAP-B
-44.50x--HK$7.14B
02256HKABBISKO-B
-11.15x300.95%HK$5.99B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.